Loading organizations...
§ Private Profile · Cambridge, MA, USA
drug discovery company developing treatments for hormone-resistant breast and prostate cancer, inhibiting FOXA1.
Azeria Therapeutics was a Cambridge, UK-based biotechnology company that developed targeted small molecule treatments for hormone-resistant breast and prostate cancers. The organization utilized a proprietary drug screening platform to selectively inhibit pioneer factors, specifically targeting the FOXA1 protein to prevent tumor growth and progression even after resistance to existing drugs had developed. Before voluntarily winding down its operations in late 2020 due to disappointing pre-clinical data, the enterprise raised approximately £37.5 million in total venture funding. This capital included an initial £4 million Series A round and a subsequent £32 million Series B financing round led by Syncona, with additional backing from Sixth Element Capital and the CRT Pioneer Fund. Following the liquidation, the company returned remaining funds to its investors. Azeria Therapeutics was founded in 2017 as a spin-out from Cancer Research UK by Professor Jason Carroll.
Azeria Therapeutics has raised $46.5M across 2 funding rounds.
Azeria Therapeutics has raised $46.5M in total across 2 funding rounds.
Azeria Therapeutics has raised $46.5M across 2 funding rounds. Most recently, it raised $41.4M Series B in November 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 21, 2019 | $41.4M Series B | Magdalena Jonikas | CRT Pioneer Fund | Announced |
| Sep 4, 2018 | $5.2M Series A | CRT Pioneer Fund | — | Announced |
Azeria Therapeutics has raised $46.5M in total across 2 funding rounds.
Azeria Therapeutics's investors include Magdalena Jonikas, CRT Pioneer Fund.